CFO
GILD icon

Cambient Family Office’s Gilead Sciences GILD Stock Holding History

Cambient Family Office’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
9,715
+142
+1% +$18.7K 0.15% 101
2026
Q1 		$1.33M Buy
9,573
+431
+5% +$60.4K 0.19% 87
2025
Q4 		$1.12M Buy
+9,142
New +$1.11M 0.16% 84

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cambient Family Office's GILD Position: Q2 2026 in Review

Cambient Family Office increased its Gilead Sciences (GILD) stake by 1.5% in Q2 2026, buying an estimated $18.7K and bringing the position to 9,715 shares worth $1.23M. The position accounts for 0.15% of the portfolio, ranked #101.

Cambient Family Office first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.33M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cambient Family Office held 9,715 shares of Gilead Sciences worth $1.23M as of Q2 2026.
  • Cambient Family Office bought 142 Gilead Sciences shares in Q2 2026, an estimated $18.7K.
  • Gilead Sciences made up 0.15% of Cambient Family Office's portfolio in Q2 2026, its #101 holding.
  • Cambient Family Office first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Cambient Family Office's Gilead Sciences position peaked at $1.33M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cambient Family Office's 13F filing for Q2 2026, filed 13 Aug 2026.